← Dashboard

Compliance Alert: Eliquis

Configure Methodology
74
Caution

Eliquis scores 74/100 (Caution) based on analysis of 60s promotional content. 3 enforcement patterns detected across Visual Distraction — “Outdoor & Physical Activity” identified at 27.4s, previously cited in BRUKINSA, COBENFY, Fasenra (x3). Weakest dimension: Visual Distraction at 44/100.

Eliquis | BMS/Pfizer | DTC Broadcast
Mar 7, 2026

Patterns Detected (3)

Matched against 14 enforcement patterns from 42 FDA letters

Visual Distraction
Outdoor & Physical Activity
Risk information must be presented in a clear, conspicuous, and neutral manner without distracting visuals
44
27.4s – 38.2s
FDA Precedent: BRUKINSA, COBENFY, Fasenra (x3), Velsipity, Calquence 21 CFR 202.1(e)(1)
Visual Distraction
Family & Social Scenes
Risk information must be presented in a clear, conspicuous, and neutral manner without distracting visuals
44
38.3s – 51.0s
FDA Precedent: Jardiance (x3), Contrave, Qulipta, Calquence, Austedo (x2) 21 CFR 202.1(e)(1)
Visual Distraction
Daily Activities
Risk information must be presented in a clear, conspicuous, and neutral manner without distracting visuals
44
9.0s – 14.2s
FDA Precedent: Contrave, Velsipity, Qulipta, Fasenra (salsa) 21 CFR 202.1(e)(1)
74
Master
44
Visual
30%
79
Efficacy
25%
93
Fair Balance
20%
100
Adeq Prov
15%
--
Lifecycle
10%
Safety Information Window
Risk disclosure: 9.9s – 58.8s (48.9s of 60.2s total — 81.3% of ad)
9.0s — Daily Activities
27.4s — Outdoor Physical
38.3s — Family Social
0s60s

Visual Evidence (3 clips)

9.0s – 14.2s Daily Activities
27.4s – 38.2s Outdoor Physical
38.3s – 51.0s Family Social

Recommendations

high
Flag for next MLR cycle: Visual content during safety information window (10s–59s) may distract from risk disclosure. Schedule creative revision to use static or neutral visuals during major statement.

Powered by cQuenced